Experts Evaluated Single-Dose HPV Vaccination
Medical researchers are reviewing single-dose efficacy for HPV protection following recent legal challenges.
Updated on Sept. 26, 2026 in Cancer
Live Poll
Should federal health agencies adopt new vaccination schedules if recent studies suggest fewer doses work?
Medical experts have launched an evaluation of a single-dose HPV vaccination schedule following a 2025 study that suggested high efficacy against cervical cancer. This review follows a contentious legal battle after a federal order to reduce the dosage requirement was blocked by a judge.
Why it matters
Simplifying the vaccination schedule to a single dose could potentially increase immunization rates, which have remained stagnant at 63% among U.S. teenagers for four years. Experts are currently investigating whether one dose offers the same long-term protection as the current two-dose regimen to ensure patient safety.
A 2025 study of 20,000 girls in Costa Rica indicated a 97% single-dose cancer protection rate, compared to the current two-dose standard. Meanwhile, nearly 50,000 HPV-related cancer cases are diagnosed annually in the U.S.
The players
Robert F. Kennedy Jr.
He serves as the U.S. health secretary and initiated the move to reduce the HPV vaccination schedule.
American Academy of Pediatrics
This professional organization represents pediatricians and filed a lawsuit against federal vaccination guidance.
Centers for Disease Control and Prevention
This federal agency is currently overseeing a work group to evaluate the scientific validity of single-dose schedules.
The details
The CDC has formed a work group to scrutinize findings that a single shot might mirror the protection levels of multiple doses. This scientific investigation follows a 2026 attempt by U.S. health secretary Robert F. Kennedy Jr. to mandate a one-dose schedule, which prompted a lawsuit from the American Academy of Pediatrics and a subsequent judicial stay.
Timeline
Federal health officials approved the first HPV vaccine in 2006.
The government shifted from a three-dose to a two-dose recommendation in 2016.
A CDC advisory committee began investigating new research in 2024.
The health secretary ordered a shift to a single-dose schedule in January 2026.
The ongoing review was discussed in a report released in September 2026.
Deeper Dive
The CDC Advisory Committee on Immunization Practices is currently weighing whether to adjust HPV dosing protocols based on emerging data. This review process follows the established methodology used by the committee to evaluate the scientific viability of changing existing vaccination standards.
Current vaccination schedules remain at two doses while the CDC continues its evaluation. Parents and patients should maintain their current immunization appointments until new, finalized guidance is issued by federal health authorities.
The takeaway
While the prospect of a single-dose vaccine could simplify medical care, current health standards require two doses for full protection. Patients should consult with their healthcare providers to ensure they are following the most recent, approved immunization protocols.
Further reading
For more information on the impact of HPV, visit the Cancer section.
Source note: This article includes information reported by Mail Online.
Live Poll
Should federal health agencies adopt new vaccination schedules if recent studies suggest fewer doses work?
